• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Beta-IFN injections in the morning may improve flu-like symptoms

September 7, 2011  

No gain with higher dose of glatiramer acetate

August 24, 2011  

Oral cladribine discontinued for MS

June 29, 2011  

MS incidence higher in African Americans

April 15, 2011  

Comorbidities common, delay MS diagnosis

April 15, 2011  

Fingolimod: disease-free rates and effect on brain atrophy

April 15, 2011  

MS patients may prefer new therapies regardless of risk

April 14, 2011  

Alemtuzumab reduces 1-year sustained disability: CAMS223 analysis

April 14, 2011  

Natalizumab discontinuation/interruption: relapse risk, poor tolerability

April 13, 2011  

3-month disability progression reduced with fingolimod

April 13, 2011  
Previous
34
35
36
37
38
Next

Browse by Topic

  • MS (414)
  • CLINICAL CASES IN MS (16)
  • EPILEPSY (36)
  • BIOMARKERS IN MS (54)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • DMT prescribing in Canada – survey results posted on June 6, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 2, 2025
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions